Related Experiment Video
Updated: May 21, 2026

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
Published on: August 19, 2016
Pathogenesis of group A streptococcal infections
Anna Henningham1, Timothy C Barnett, Peter G Maamary
1School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, University of Queensland, St. Lucia, Queensland 4072, Australia.
Group A Streptococcus (GAS) causes serious global health issues, from mild infections to life-threatening conditions. A GAS vaccine is crucial for future control due to antibiotic resistance concerns.
Area of Science:
- Microbiology
- Infectious Diseases
- Public Health
Background:
- Group A Streptococcus (GAS), or Streptococcus pyogenes, is a significant human pathogen responsible for global morbidity and mortality.
- GAS infections range from common pharyngitis and impetigo to severe conditions like necrotizing fasciitis, streptococcal toxic shock syndrome (STSS), and bacteremia.
- Repeated GAS infections can lead to severe non-suppurative sequelae, including acute rheumatic fever and acute glomerulonephritis.
Purpose of the Study:
- To highlight the global health impact of Group A Streptococcus infections.
- To discuss the limitations of current antibiotic treatments for GAS.
- To emphasize the potential of a GAS vaccine for future disease control.
Main Methods:
- This is a review and discussion of existing literature on GAS epidemiology, clinical manifestations, and treatment challenges.
- Analysis of the current sensitivity of GAS to penicillin and concerns regarding emerging resistance.
- Evaluation of the potential role of vaccination in preventing GAS infections.
Main Results:
- GAS infections present a wide spectrum of disease severity and can lead to long-term complications.
- Penicillin remains effective but faces challenges from patient compliance and potential antibiotic resistance.
- Vaccination is proposed as a critical future strategy for controlling GAS.
Conclusions:
- Group A Streptococcus poses a substantial global health burden, necessitating effective control strategies.
- The emergence of antibiotic resistance and compliance issues underscore the need for alternative prevention methods.
- A vaccine for GAS is essential for the future control and potential elimination of GAS-related diseases.
Related Concept Videos
Staphylococcal Skin Infections
Rheumatic Heart Disease I: Introduction
Bacterial Meningitis II: Pathophysiology
Diphtheria
Gastritis II: Pathophysiology
Regulation of Bacterial Virulence